Final 5-Year Updated Results From a Phase 3 Study (HELIOS) of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2019年 / 17卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 19
页数：3
相关论文
共 50 条
  • [31] Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study
    Hallek, Michael
    Fraser, Graeme
    Cramer, Paula
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Mayer, Jiri
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Bartlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Mahler, Michelle
    Phelps, Charles
    Salman, Mariya
    Howes, Angela
    Chanan-Khan, Asher
    LEUKEMIA & LYMPHOMA, 2017, 58 : 192 - 194
  • [32] Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Laliberte, Francois
    BLOOD, 2022, 140 : 10911 - 10912
  • [33] IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY
    Cramer, P.
    Chanan-Khan, A.
    Demirkan, F.
    Fraser, G.
    Santucci Silva, R.
    Pylypenko, H.
    Grosicki, S.
    Janssens, A.
    Pristupa, A.
    Mayer, J.
    Dilhuydy, M. S.
    Loscertales, J.
    Bartlett, N. L.
    Avigdor, A.
    Rule, S.
    Sun, S.
    Mahler, M.
    Salman, M.
    Howes, A.
    Hallek, M.
    HAEMATOLOGICA, 2015, 100 : 55 - 56
  • [34] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Flinn, Ian W.
    de Vos, Sven
    Barrientos, Jacqueline C.
    Schreeder, Marshall T.
    Wagner-Johnson, Nina D.
    Sharman, Jeff P.
    Boyd, Thomas E.
    Fowler, Nathan
    Dreiling, Lyndah
    Kim, Yeonhee
    Mitra, Siddhartha
    Rai, Kanti
    Leonard, John P.
    Furman, Richard R.
    HEMASPHERE, 2018, 2 (03):
  • [35] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [36] First Interim Analysis Of ALPINE Study: Results Of A Phase 3 Randomized Study Of Zanubrutinib Vs Ibrutinib In Patients With Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL)
    Hillmen, Peter
    Eichhorst, Barbara
    Brown, Jennifer R.
    Lamanna, Nicole
    O'brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Ji, Meng
    Yecies, Jessica
    Wu, Kenneth
    Novotny, William
    Huang, Jane
    Jurczak, Wojciech
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 143 - 144
  • [37] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Chavez, Julio C.
    Piris-Villaespesa, Miguel
    Dalia, Samir
    Powers, John
    Turba, Elyce
    Nodzon, Lisa
    Komrokji, Rami
    Sokol, Lubomir
    Locke, Frederick L.
    Lancet, Jeffrey
    Sotomayor, Eduardo M.
    Kharfan-Dabaja, Mohamed A.
    Pinilla-Ibarz, Javier
    LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
  • [38] Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia-Results From Pre-Planned Interim Analysis of the Randomized Phase 3 MURANO Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 12 - 14
  • [39] ASCEND Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib or Bendamustine in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 21 - 22
  • [40] ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF ASCEND
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Jurcza, Wojciech
    HAEMATOLOGICA, 2020, 105 : 205 - 206
12345